MULTIFOCAL INFLAMMATORY LEUKOENCEPHALOPATHY WITH 5-FLUOROURACIL AND LEVAMISOLE

被引:119
|
作者
HOOK, CC
KIMMEL, DW
KVOLS, LK
SCHEITHAUER, BW
FORSYTH, PA
RUBIN, J
MOERTEL, CG
RODRIGUEZ, M
机构
[1] MAYO CLIN & MAYO FDN, DEPT NEUROL, 200 1ST ST SW, ROCHESTER, MN 55905 USA
[2] MAYO CLIN & MAYO FDN, DIV MED ONCOL, ROCHESTER, MN 55905 USA
[3] MAYO CLIN & MAYO FDN, SURG PATHOL SECT, ROCHESTER, MN 55905 USA
关键词
D O I
10.1002/ana.410310306
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
A cerebral demyelinating disease developed in 3 patients during adjuvant therapy with 5-fluorouracil and levamisole for adenocarcinoma of the colon. None of the patients had evidence of metastatic disease or prior neurological disease. The duration of chemotherapy before onset of neurological symptoms ranged from 15 to 19 weeks. The total dose of 5-fluorouracil was 9.7 to 15.7 gm. The total dose of levamisole was 2.7 to 3.75 gm. Two patients presented with a subacute (2-3 weeks) progressive decline in mental status and ataxia. The third patient had two unexplained episodes of loss of consciousness. In each, magnetic resonance imaging with gadolinium demonstrated prominent multifocal enhancing white matter lesions. Cerebral biopsy was performed stereotaxically in 2 patients. The morphological features were those of active demyelinating disease. The myelin loss was associated with numerous dispersed as well as vasocentric macrophages, sparing of axons, and perivascular lymphocytic inflammation. Electron microscopy confirmed the light microscopic findings. All 3 patients improved after cessation of chemotherapy and a short course of corticosteroid therapy. Our patients represent the first reported examples of an inflammatory leukoencephalopathy associated with the administration of 5-fluorouracil and levamisole. This syndrome may represent the pathological basis for 5 fluorouracil neurotoxicity, although we cannot completely exclude the role of levamisole.
引用
收藏
页码:262 / 267
页数:6
相关论文
共 50 条
  • [21] Adjuvant chemotherapy in stage III colon cancer with 5-fluorouracil and levamisole versus 5-fluorouracil and leucovorin
    Dencausse, Y
    Hartung, G
    Sturm, J
    Kopp-Schneider, A
    Hagmüller, E
    Wojatschek, C
    Lindemann, H
    Fritze, D
    Queisser, W
    ONKOLOGIE, 2002, 25 (05): : 426 - 430
  • [22] Pharmacokinetics of levamisole in cancer patients treated with 5-fluorouracil
    Gwilt, P
    Tempero, M
    Kremer, A
    Connolly, M
    Ding, C
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 45 (03) : 247 - 251
  • [23] A phase I study of 5-fluorouracil, leucovorin and levamisole
    Cleary, JF
    Arzoomanian, R
    Alberti, D
    Feierabend, C
    Storer, B
    Witt, P
    Carbone, P
    Wilding, G
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1997, 39 (04) : 300 - 306
  • [24] MULTIFOCAL INFLAMMATORY LEUKENCEPHALOPATHY CAUSED BY ADJUVANT THERAPY WITH 5-FLUOROURACIL AND LEVAMISOLE AFTER RESECTION FOR AN ADENOCARCINOMA OF THE COLON (VOL 87, PG 70, 1993)
    NEU, IS
    ACTA NEUROLOGICA SCANDINAVICA, 1993, 88 (03): : 239 - 239
  • [25] INFLAMMATORY LEUKOENCEPHALOPATHY CAUSED BY ADJUVANT THERAPY WITH 5-FLUOROURACIL AND LEVAMISOL FOR COLON-CARCINOMA
    FERROIR, JP
    FENELON, G
    BEAUGERIE, L
    RECOING, DA
    REVUE NEUROLOGIQUE, 1994, 150 (6-7) : 471 - 474
  • [26] Pharmacokinetics of levamisole in cancer patients treated with 5-fluorouracil
    Peter Gwilt
    Margaret Tempero
    Alton Kremer
    Mary Connolly
    Cliff Ding
    Cancer Chemotherapy and Pharmacology, 2000, 45 : 247 - 251
  • [27] Confirmed case of levamisole-associated multifocal inflammatory leukoencephalopathy in a cocaine user
    Vitt, Jeffrey R.
    Brown, Ethan G.
    Chow, Daniel S.
    Josephson, S. Andrew
    JOURNAL OF NEUROIMMUNOLOGY, 2017, 305 : 128 - 130
  • [28] The role of levamisole in the adjuvant treatment of stage III colon cancer patients: A randomized trial of 5-fluorouracil and levamisole versus 5-fluorouracil alone
    Cascinu, S
    Catalano, V
    Piga, A
    Mattioli, R
    Marcellini, M
    Pancotti, A
    Bascioni, R
    Torresi, U
    Silva, RR
    Pieroni, V
    Giorgi, F
    Catalano, G
    Cellerino, R
    CANCER INVESTIGATION, 2003, 21 (05) : 701 - 707
  • [29] Leukoencephalopathy induced by chemotherapy with tegafur, a 5-fluorouracil derivative
    Ohara, S
    Hasashi, R
    Hata, S
    Itoh, N
    Hanyu, N
    Yamamoto, K
    ACTA NEUROPATHOLOGICA, 1998, 96 (05) : 527 - 531
  • [30] Lethal leukoencephalopathy secondary to Tegafur, a 5-fluorouracil prodrug
    Sierra, Salvador
    Luquin, Natasha
    Carrato, Cristina
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2015, 357 (1-2) : 326 - 328